Form 4: Carlyle Group Sells Shares of QuidelOrtho Corp (QDEL) Under 10b5-1 Trading Plan

Carlyle Group executed sales of QuidelOrtho Corp (QDEL) common stock on August 9, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Carlyle Group, a significant shareholder of QuidelOrtho Corp (QDEL), has reported the sale of shares on August 9, 2024.
• The sales were executed under a pre-existing Rule 10b5-1 trading plan adopted on May 12, 2024.
• A total of 6,344 shares were sold at a weighted average price of $40.8064, with individual prices ranging from $40.65 to $40.9885.
• An additional 67,790 shares were sold at a weighted average price of $41.6006, with individual prices ranging from $41.01 to $41.89.
• Following these transactions, Carlyle Group's indirect beneficial ownership stands at 8,260,183 shares.
• The reporting entities, including Carlyle Group Inc. and its affiliates, have disclaimed beneficial ownership of the securities held of record by Carlyle Partners VI Cayman Holdings, L.P.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing share sales. It doesn't convey any explicit positive or negative sentiment about the company's prospects. The sales are part of a pre-arranged plan, so they don't necessarily indicate a change in Carlyle's long-term view.

Risks

• The sale of shares by a major shareholder like Carlyle Group could potentially exert downward pressure on QDEL's stock price in the short term.
• The market may interpret the sale as a change in Carlyle Group's investment outlook on QuidelOrtho Corp.

Future Outlook

The document does not contain any specific forward-looking statements regarding QuidelOrtho Corp's future performance or Carlyle Group's future transactions.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies and their major shareholders, providing transparency into insider transactions. The sale by Carlyle Group is not necessarily indicative of a negative outlook on QuidelOrtho, as it could be part of a pre-planned diversification strategy or fund management decision.

Comparison to Industry Standards

• Comparing Carlyle's sale to similar transactions by other major shareholders in the diagnostics industry would require analyzing their Form 4 filings and investment strategies.
• It's important to consider the size of the sale relative to Carlyle's total holdings and the overall trading volume of QDEL shares.
• Benchmarking against other private equity firms' exits from healthcare investments could provide additional context.

Stakeholder Impact

• Shareholders may react to the news of Carlyle Group's share sales, potentially leading to short-term price volatility.
• The impact on employees, customers, suppliers, and creditors is likely to be minimal, as the transaction is a financial one and doesn't directly affect the company's operations.

Key Dates